


INI-1

Control Slides



Intended Use

For In Vitro Diagnostic Use.

Summary and Explanation

The INI-1 gene, which encodes a functionally uncharacterized protein component of the hSWI/SNF chromatin remodeling complex, is involved in chromatin remodeling and transcriptional regulation and also known as hSNF5, SMARCB1 and BAF47. INI-1 is often mutated or deleted in malignant rhabdoid tumor. Two isoforms of INI-1, that differ by the variable inclusion of amino acids, potentially are produced by differential RNA splicing. The morphology of malignant rhabdoid tumors can present challenges in differential diagnosis. The overall survival of MRTs relative to its potential mimics such as medulloblastoma and supratentorial primitive neuroectodermal tumors is quite low, and thus differentiation from these other tumors is desirable. Lack of nuclear labeling by INI-1 is characteristic of malignant rhabdoid tumors. The majority of medulloblastomas and supratentorial primitive neuroectodermal tumors are labeled by INI-1. Malignant rhabdoid tumors also originate from the kidney and soft tissues. Germline INI-1 mutations are associated with sporadic schwannomatosis and rhabdoid tumors. INI-1 has been used to distinguish atypical teratoid / rhabdoid tumor (loss of INI1) from choroid plexus carcinoma (positive for INI-1) and to differentiate epithelioid sarcoma (loss of INI1) from epithelioid hemangioendothelioma (positive for INI-1).

Presentation

Five slides of INI-1 positive tissues, each mounted on Hydrophilic Plus Slides, provided in a plastic mailer.

<i>Catalog No.</i>	<i>Quantity</i>
BSB-9244-CS	5 slides
BSB 6834	5 slides
BSB-3779-CS	5 slides

Storage Store at 20-25°C

Precautions

1. For professional users only. Results should be interpreted by a qualified medical professional.
2. Ensure proper handling procedures are used with this reagent.
3. Always wear personal protective equipment such as a laboratory coat, goggles, and gloves when handling reagents.
4. Dispose of unused solution with copious amounts of water.
5. Follow safety precautions of the heating device used for epitope retrieval (TintoRetriever Pressure Cooker or similar).
8. For additional safety information, refer to Safety Data Sheet for this product.
9. For complete recommendations for handling biological specimens, please refer to the CDC document, "Guidelines for Safe Work Practices in Human and Animal Medical Diagnostic Laboratories" (see References in this document).

Stability

This product is stable up to the expiration date on the product label.

Do not use after expiration date listed on package label.

IHC Protocol

1. Subject tissues to heat induced epitope retrieval (HIER) using a suitable retrieval solution such as ImmunoDNA Retriever with Citrate (BSB 0020-BSB 0023) or EDTA (BSB 0030-BSB 0033).

2. Any of three heating methods may be used:

a. TintoRetriever Pressure Cooker or Equivalent

Place tissues/slides in a staining dish or coplin jar containing the ImmunoDNA Retriever with Citrate or EDTA and place on trivet in the pressure cooker. Add 1-2 inches of distilled water to the pressure cooker and turn heat to high. Incubate for 15 minutes. Open and immediately transfer slides to room temperature.

b. TintoRetriever PT Module or Water Bath Method

Place tissues/slides in a pre-warmed staining dish or coplin jar containing the ImmunoDNA Retriever with Citrate or EDTA at 95°-99° C. Incubate for 30-60 minutes.

c. Conventional Steamer Method

Place tissues/slides in a pre-warmed staining dish or coplin jar containing the ImmunoDNA Retriever with Citrate or EDTA in a steamer, cover and steam for 30-60 minutes.

3. After heat treatment, transfer slides in ImmunoDNA Retriever with Citrate or EDTA to room temperature and let stand for 15-20 minutes.
4. For manual staining, perform antibody incubation at ambient temperature. For automated staining methods, perform antibody incubation according to instrument manufacturer's instructions.
5. Wash slides with ImmunoDNA washer or DI water.
6. Continue IHC staining protocol. Wash slides between each step with ImmunoDNA washer solution.

Abbreviated Immunohistochemical Protocol

Step	ImmunoDetector AP/HRP	PolyDetector AP/HRP	PolyDetector Plus HRP
Peroxidase/AP Blocker	5 min.	5 min.	5 min
Primary Antibody	30-60 min.	30-60 min.	30-60 min.
1st Step Detection	10 min.	30-45 min.	15 min.
2nd Step Detection	10 min.	Not Applicable	15 min.
Substrate- Chromogen	5-10 min.	5-10 min.	5-10 min.
Counterstain / Coverslip	Varies	Varies	Varies

Abbreviated IF Protocol

Step	Incubation Time
Rinse slides in IF wash buffer	5 minutes
Drain and wipe excess IF wash buffer off slide	
Conduct remaining steps in the dark	
Apply Antibody	30-60 minutes
Rinse with 3 changes of IF wash buffer	3x15 minutes each
Coverslip with IF mounting medium	

Mounting Protocols

For detailed instructions using biodegradable permanent mounting media such as XyGreen PermaMunter (BSB 0169-0174) or organic solvent based resin such as PermaMunter (BSB 0094-0097), refer to PI0174 or PI0097.

Product Limitations

Due to inherent variability present in immunohistochemical procedures (including fixation time of tissues, dilution factor of antibody, retrieval method utilized, and incubation time), optimal performance should be established through the use of positive and negative controls. Results should be interpreted by a qualified medical professional.

References

1. Bourdeaut F, Fréneaux P, Thuille B, et al. hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities. *J Pathol.* 2007;211(3):323-330. doi:10.1002/path.21032. Fowler DJ, Malone M, Chisholm J, Roebuck D, Sebire NJ. Primary thoracic myxoid variant of extrarenal rhabdoid tumor in childhood. *Fetal Pediatr Pathol.* 2006;25(3):159-168. doi:10.1080/155138106009083883. Haberler C, Laggner U, Slavc I, et al. Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: Lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype. *Am J Surg Pathol.* 2006;30(11):1462-1468. doi:10.1097/01.pas.0000213329.71745.ef4. Rousseau G, Noguchi T, Bourdon V, Sobol H, Olschwang S. SMARCB1/INI1 germline mutations contribute to 10% of sporadic schwannomatosis. *BMC Neurol.* 2011;11:9. Published 2011 Jan 24. doi:10.1186/1471-2377-11-95. Bourdeaut F, Lequin D, Brugières L, et al. Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor. *Clin Cancer Res.* 2011;17(1):31-38. doi:10.1158/1078-0432.CCR-10-17956. Judkins AR, Burger PC, Hamilton RL, et al. INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. *J Neuropathol Exp Neurol.* 2005;64(5):391-397. doi:10.1093/jnen/64.5.3917. Hornick JL, Dal Cin P, Fletcher CD. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. *Am J Surg Pathol.* 2009;33(4):542-550. doi:10.1097/PAS.0b013e3181882c548. U.S. Department of Health and Human Services: Centers for Disease Control and Prevention. Guidelines for Safe Work Practices in Human and Animal Medical Diagnostic Laboratories. Supplement / Vol. 61, January 6, 2012. <https://www.cdc.gov/mmwr/pdf/other/su6101.pdf>

Symbol Key / Légende des symboles/Erläuterung der Symbole

EC REP QAdvis EAR AB Ideon Science Park Scheelevägen 17 SE-223 70 Lund, Sweden	 Storage Temperature Limites de température Zulässiger Temperaturbereich	 Manufacturer Fabricant Hersteller	REF Catalog Number Référence du catalogue Bestellnummer
IVD In Vitro Diagnostic Medical Device Dispositif médical de diagnostic in vitro In-Vitro-Diagnostikum	 Read Instructions for Use Consulter les instructions d'utilisation Gebrauchsanweisung beachten	 Expiration Date Utiliser jusque Verwendbar bis	LOT Lot Number Code du lot Chargenbezeichnung